BUY Aurobindo Pharma — Ajit Mishra, 12 Oct 2026

BUYAurobindo Pharma

Aurobindo Pharma share price target & all analyst calls

byAjit Mishra, ReligareHorizon: Swing (≤2wk)12 Oct 2026via NDTV Profit (Live)

Entry₹1,692.5Inferred

Target₹1,820

Total upside +7.53%

Stop loss₹1,620-4.28% risk

CMP₹1,706.9Just now

Active+0.85%+6.63%upside left 14d left

Follow Ajit Mishra for new calls(23% target hit, 105 closed calls)Get alerts Watch AUROPHARMA for new buy/sell callsGet alerts See 3 other Swing calls on AUROPHARMA See 83 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 12 Oct, 4:44 pm IST

11 supporting2 neutral1 opposing

Supports the BUY call (11)

3 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·12 Oct · today

Aurobindo Pharma Shares in Focus After USFDA Approval for Perampanel

NewsGoogle News·5 Oct · 1w ago

Aurobindo Pharma USFDA Approval Sparks Rally to New 52-Week High

NewsGoogle News·5 Oct · 1w ago

Aurobindo Pharma rises on getting USFDA`s final nod to manufacture, market Perampanel tablets

NewsGoogle News·5 Oct · 1w ago

Aurobindo Pharma Gets USFDA Nod for Generic Epilepsy Tablets

NewsGoogle News·5 Oct · 1w ago

Neutral / worth noting (2)

These four pharma stocks will be reacting to important news updates today

NewsCnbc-Tv18·5 Oct · 1w ago

Aurobindo Pharma Ltd has announced the acquisition of a step-down subsidiary located in the USA.

BSE · Company Update·2 Oct · 1w ago

Weighs against the BUY call (1)

MACD below its signal line — bearish momentum

Technicals · macd·12 Oct · today

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Aurobindo Pharma

All analyst calls on Aurobindo Pharma

More from Ajit Mishra, Religare

Every call and its outcome

BUY Aurobindo Pharma — Ajit Mishra, Religare

AI Assessment

Other calls on Aurobindo Pharma

More from Ajit Mishra, Religare